One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy

被引：0
|
作者：
Sandborn, William J.
Rutgeerts, Paul J.
Reinisch, Walter
Mantzaris, Gerassimos J.
Kornbluth, Asher
Rachmilewitz, Daniel
Lichtiger, Simon
D'Haens, Geert R.
van der woude, Christien J.
Diamond, Robert
Broussard, Delma
Tang, Kezhen L.
Colombel, Jean-Frederic
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
    Ye, Byong Duk
    Pesegova, Marina
    Alexeeva, Olga
    Osipenko, Marina
    Lahat, Adi
    Dorofeyev, Andriy
    Fishman, Sigal
    Levchenko, Olena
    Cheon, Jae Hee
    Scribano, Maria Lia
    Mateescu, Radu-Bogdan
    Lee, Kang-Moon
    Eun, Chang Soo
    Lee, SangJoon
    Lee, Sung Young
    Kim, HoUng
    Schreiber, Stefan
    Fowler, Heather
    Cheung, Raymond
    Kim, Young-Ho
    LANCET, 2019, 393 (10182): : 1699 - 1707
  • [42] Adding infliximab to triple DMARD plus predmisolone therapy reduces absence from work in patients with early active rheumatoid arthritis.: Results from a double-blind placebo-controlled study (NEORACo)
    Leirisalo-Repo, Marjatta
    Kautiainen, Hannu
    Mottonen, Timo
    Hannonen, Pekka
    Korpela, Markku
    Kauppi, Markku
    Kaipiainen-Seppaenen, Oili
    Puolakka, Kari
    Uusitalo, Tea
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S537 - S538
  • [43] Souvenaid® Improves Memory in Drug-Naive Patients with Mild Alzheimer's Disease: Results from a Randomized, Controlled, Double-Blind Study (Souvenir II)
    Scheltens, P.
    Twisk, J.
    Blesa, R.
    Scarpini, E.
    Von Arnim, C.
    Bongers, A.
    Harrison, J.
    Swinkels, S.
    De Deyn, P.
    Wieggers, R.
    Vellas, B.
    Kamphuis, P.
    JOURNAL OF ALZHEIMERS DISEASE, 2012, 29 : 37 - 38
  • [44] ACHIEVEMENT OF LOW DISEASE ACTIVITY (LDA) AT 3 MONTHS PREDICTS CLINICAL REMISSION (REM) AT 1 YEAR OF INFLIXIMAB (IFX) THERAPY IN RA: POST-HOC ANALYSIS OF A RANDOMIZED DOUBLE-BLIND CLINICAL STUDY (RISING STUDY)
    Takeuchi, T.
    Yano, T.
    Inui, T.
    Yoshinari, T.
    Miyasaka, N.
    Abe, T.
    Koike, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 439 - 440
  • [45] A Randomized, Double-Blind Phase III Study Comparing the Efficacy, Safety and Immunogenicity of PF-06438179/GP1111 (Ixifi™), an Infliximab Biosimilar, and Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Active RA: Results from Week 54 to Week 78
    Cohen, Stanley
    Kivitz, Alan J.
    Tee, Michael
    Cronenberger, Carol
    Zhang, Min
    Hackley, Sarah
    Schumacher, Karl
    Rehman, Muhammad I.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [46] Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.
    Fleischmann, Roy
    Decktor, Dennis L.
    Fan, Chunpeng
    Van Hoogstraten, Hubert
    Genovese, Mark C.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1232 - S1233
  • [47] Donepezil reduces the time caregivers spend providing care: Results of a one-year, double-blind randomized trial in patients with mild to moderate Alzheimer's disease.
    Mastey, V
    Wimo, A
    Winblad, B
    Haglund, A
    Jacobson, L
    Miceli, R
    Zhang, R
    Subbiah, P
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S20 - S20
  • [48] A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI
    Sandborn, William
    Feagan, Brian G.
    Gasink, Christopher
    Jacobstein, Douglas
    Gao, Long-Long
    Johanns, Jewel
    Sands, Bruce E.
    Hanauer, Stephen B.
    Targan, Stephan
    Ghosh, Subrata
    de Villiers, Willem J.
    Colombel, Jean-Frederic
    Lee, Scott
    Dieleman, Levinus A.
    Katz, Seymour
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2016, 150 (04) : S157 - S158
  • [49] A Randomized, Double-blind, Active-and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Antirheumatic Drugs with Active Psoriatic Arthritis
    Mease, Philip
    van der Heijde, Desiree
    Ritchlin, Christopher
    Cuchacovich, Raquel
    Shuler, Catherine
    Lin, Chen-Yen
    Vangerow, Harald
    Samanta, Suvajit
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1169 - 1169
  • [50] Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Crohn's Disease: Results From the Phase 3 Randomized, Double-Blind, Placebo-Controlled DIVERSITY1 Study
    Vermeire, Severine
    Rubin, David T.
    Watanabe, Mamoru
    Schreiber, Stefan
    Mehta, Rajiv
    Roblin, Xavier
    Genovese, Mark C.
    Masior, Tomasz
    Barron, Rahul
    Le Brun, Franck-Olivier
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S673 - S675
12345